Stockwatch

Date	Sym	Type	Headline
2024-03-22 07:00	UU:RDY	News Release200	Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
2024-03-19 07:00	UU:RDY	News Release200	Dr. Reddy's Laboratories launches Versavo(TM) (bevacizumab) in the UK
2024-01-31 09:44	UU:RDY	News Release200	Dr. Reddy ¢ € ™s Q3 & 9M FY24 Financial Results
2024-01-03 06:00	UU:RDY	News Release200	Dr. Reddy's Announces the Acquisition of MenoLabs ‚ ®, a Leading Women ¢ € ™s Health and Dietary Supplements Portfolio of Brands
2023-12-14 07:49	UU:RDY	News Release200	Dr. Reddy ¢ € ™s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
2023-12-06 07:00	UU:RDY	News Release200	Coya Therapeutics, Inc. and Dr. Reddy ¢ € ™s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
2023-10-27 13:50	UU:RDY	News Release200	Dr. Reddy ¢ € ™s Q2 FY24 Financial Results
2023-08-10 07:00	UU:RDY	News Release200	Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
2023-07-26 12:31	UU:RDY	News Release200	Dr. Reddy ¢ € ™s Q1 FY24 Financial Results
2023-07-12 10:25	UU:RDY	News Release200	Dr. Reddy ¢ € ™s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
2023-06-05 07:00	UU:RDY	News Release200	Dr. Reddy ¢ € ™s Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab
2023-05-10 11:43	UU:RDY	News Release200	Dr. Reddy ¢ € ™s Q4 & FY23 Financial Results
2023-05-05 07:17	UU:RDY	News Release200	Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.